What exactly is eflornithine?

Eflornithine tablets (eflornithine) is a new type of oral irreversible inhibitor of ornithine decarboxylase (ODC). Its mechanism mainly regulates cell division and growth by inhibiting the polyamine synthesis pathway. The drug was first used to treat late-stage African trypanosomiasis caused by Trypanosoma gambiae. Later, clinical studies found that it also has potential therapeutic effects in some solid tumors and pediatric neuroblastoma (HRNB). Currently, eflornithine tablets are being repositioned as a targeted therapy drug, mainly used to treat high-risk neuroblastoma patients, especially those who are still at risk of recurrence after receiving multimodal regimens including chemotherapy, surgery, radiotherapy and anti-GD2 immunotherapy. The U.S. FDA supports the drug in the Orphan Drug Program and Priority Approval Pathway.

As an adjuvant treatment drug for high-risk neuroblastoma, eflornithine does not rely on traditional cytotoxic mechanisms. Instead, it interferes with tumor cell metabolism by inhibitingODC, a key enzyme that regulates intracellular polyamine balance, thereby delaying disease progression. Studies have shown that the expression level of ODC in neuroblastoma cells is significantly increased and is closely related to the risk of recurrence. Therefore, inhibiting ODC activity has become an important target. Eflornithine is given in the form of tablets and can be effectively distributed in body tissues after oral administration. It has a certain penetration ability into the central nervous system, which is particularly critical for the treatment of neurogenic tumors.

In clinical practice, the use of this drug is usually in the maintenance treatment phase, with the purpose of prolonging the patient's disease-free survival and reducing the risk of tumor recurrence. Because its targeting mechanism is different from traditional chemotherapy, eflornithine has low overall toxicity to the body and is suitable for long-term management programs. Although its current indications are still relatively limited, it has been regarded as an emerging treatment option with important promise in the fields of pediatric oncology and rare diseases.

Reference materials:https://www.drugs.com/mtm/eflornithine.html